drugset / Trial / NCT00417287
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Phase 2
Terminated
17 enrolled
Cascadian Therapeutics Inc.
National Cancer Institute (NCI) · collabTranslational Genomics Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to evaluate the clinical efficacy, biologic activity (inhibition of PX-12 target thioredoxin-1) and effects of an expired metabolite of PX-12 in patients with advanced pancreatic cancer.
Timeline
- Start
- 2006-12
- Primary completion
- 2009-04
- Completion
- 2009-04
Outcome
Outcome not reported
Stopped: “Investigator decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PX-12 | Small molecule | 54 mg/m2 | Intravenous |
| Comparator | PX-12 | Small molecule | 128 mg/m2 | Intravenous |